Oncotelic Therapeutics is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that Oncotelic is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These two approaches (VDAs and AAs) have distinct, yet complementary mechanisms of action. At Oncotelic, we believe that we can significantly improve cancer therapy by combining these 2 complementary approaches.